Two more mainland pharmaceutical firms are reportedly proceeding with their initial public offerings in Hong Kong, joining the city’s strong listing pipeline.
Biotech company MediLink Therapeutics has mandated China International Capital Corporation (3908), JPMorgan Chase, and Morgan Stanley to prepare for the listing, Bloomberg News reported.
MediLink was said to plan to raise US$100 million (HK$780 million).
Founded in July 2020, MediLink is an innovative drug discovery and development company focusing on antibody drug coupling and related technologies, with research and development centers in Shanghai and Boston, according to its official website.
At the same time, Bayzed Health Group is conducting pre-IPO roadshows, after passing its hearing last week, local media reported.
Bayzed plans to raise US$100 million from its share sale.
Earlier today, Hong Kong’s Financial Secretary Paul Chan Mo-po said the city’s IPO pipeline is “very strong.”
Hong Kong Exchanges and Clearing (0388) last month said more than 150 firms are waiting to go public in the city.
STAFF REPORTER
